Cookie Settings

We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .


These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name Webedition CMS
Purpose This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name econda
Purpose Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name econda
Purpose Statistics
External media

Content from external media platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name YouTube
Purpose Show YouTube content
Name Twitter
Purpose activate Twitter Feeds

HP-F6: 'Oncolytic Viruses' and 'Gene Therapy'

Type: Practical Course with Student Seminars

Weeks 1-2: Oncolytic Viruses

Date: 22. January - 2. February 2024

Hosts/Supervisors: Jürg Nüesch (responsible organizer contact:, Mathias Leber, Dirk Nettelbeck, Guy Ungerechts



Virotherapy represents a novel modality for cancer treatment based on tumor-selective virus infection, replication and spread (therefore also called Viral Oncolysis). Key advantages of this strategy are the implementation of a distinct means of cancer cell killing, amplification of the therapeutic agent in the patients’ tumor, and the opportunity to engineer the virus drug to match specific applications (for example virus capsid modification for targeted cell entry, insertion of therapeutic genes into the viral genome).



Principles of viral oncolysis as well as different oncolytic viruses will be introduced in a morning seminar by the group leaders of DKFZ virotherapy groups. The students will be provided with recent literature, which they will present in the seminar. Practical work will be performed in groups of two students in the different DKFZ virotherapy groups. Students will apply molecular biology, immunology, cell biology and virology techniques to address a scientific topic of oncolytic virus development or characterization.

Week 3: Gene Therapy/Adeno-Associated Virus (AAV)

Date: 19.-23 February 2024

Host: Dirk Grimm and co-workers (contact:

Topics and Content:

Gene therapy - Knockdown by RNAi and knockout by CRISPR

to top
powered by webEdition CMS